Trial Profile
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL003 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2022
Price :
$35
*
At a glance
- Drugs AL 003 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Alector
- 26 Apr 2022 Results assessing safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL003 in healthy volunteers (HV) and patients with mild to moderate AD presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 15 Sep 2021 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Status changed from recruiting to active, no longer recruiting.